yes... and mabs.... my guess is most batches at this stage would be for trials etc... bottom line is covid has used up capacity on industry wide basis for the short term.
this should impact all uses whether cancer research etc..
how avid is impacted remains to be seen (at least by shareholders)...
News 
Market Data 
Discover 
